Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti-PD1 Therapy in High-Risk Resectable Melanoma
Source: OncLive, April 2024
Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.
Dual checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) led to higher rates of pathological and radiologic response vs anti-PD1 monotherapy but was associated with more grade 3 or 4 immune-related adverse effects (irAEs), in patients with high-risk resectable melanoma, according to findings from a pooled analysis published in JAMA Oncology.
Patients in the neoadjuvant dual checkpoint inhibitor cohort (n = 204) experienced a radiologic overall objective response (rOOR) of 50.0% vs 45.6% in the neoadjuvant anti–PD-1 cohort (n = 160). Investigators noted that although the radiologic complete response (rCR) rate was higher in the combination arm vs anti–PD-1 monotherapy arm (10.29% vs 5.63%), there was not a statistically significant difference between the 2 groups in terms of the odds of obtaining an rCR (OR, 1.93; 95% CI, 0.86-4.33; P = .11) or rOOR (OR, 1.19; 95% CI, 0.79-1.81; P =.41). There was also not a statistically significant difference regarding progressive disease rates (11.8% vs 15.6%) in the two cohorts, respectively (OR, 0.72; 95% CI, 0.39-1.32; P = .29).